CERC Key Statistics, Chart & Performance
The current stock price of CERC is 2.93 null. In the past month the price increased by 6.55%. In the past year, price increased by 15.35%.
CERC Latest News, Press Relases and Analysis
CERC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.57 | 988.98B | ||
| JNJ | JOHNSON & JOHNSON | 19.79 | 494.92B | ||
| MRK | MERCK & CO. INC. | 11.47 | 250.76B | ||
| PFE | PFIZER INC | 7.86 | 143.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.36 | 98.22B | ||
| ZTS | ZOETIS INC | 19.63 | 54.84B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.82B | ||
| VTRS | VIATRIS INC | 4.6 | 12.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.43 | 11.17B | ||
| CORT | CORCEPT THERAPEUTICS INC | 91.77 | 8.50B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.16B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.26B |
Related stock screener links
About CERC
Company Profile
Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2015-11-13. The firm is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The firm is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.
Company Info
Cerecor Inc
540 Gaither Rd Ste 400
Rockville MARYLAND 20850 US
CEO: Michael Cola
Employees: 32
Phone: 14105228707.0
Cerecor Inc / CERC FAQ
What does Cerecor Inc do?
Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2015-11-13. The firm is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The firm is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.
Can you provide the latest stock price for Cerecor Inc?
The current stock price of CERC is 2.93 null. The price decreased by -1.68% in the last trading session.
Does Cerecor Inc pay dividends?
CERC does not pay a dividend.
What is the ChartMill rating of Cerecor Inc stock?
CERC has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
On which exchange is CERC stock listed?
CERC stock is listed on the Nasdaq exchange.
CERC Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CERC. When comparing the yearly performance of all stocks, CERC turns out to be only a medium performer in the overall market: it outperformed 48.14% of all stocks.
CERC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CERC. CERC has a bad profitability rating. Also its financial health evaluation is rather negative.
CERC Financial Highlights
Over the last trailing twelve months CERC reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS decreased by -49.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1194.83% | ||
| ROA | -119.98% | ||
| ROE | N/A | ||
| Debt/Equity | 0.79 |
CERC Forecast & Estimates
4 analysts have analysed CERC and the average price target is 6.63 null. This implies a price increase of 126.28% is expected in the next year compared to the current price of 2.93.
For the next year, analysts expect an EPS growth of 4.09% and a revenue growth -12.27% for CERC